catalym
Posted by catalym
January 8, 2024
catalym
Posted by catalym
December 6, 2023
trophic
Posted by trophic
October 31, 2023
catalym
Posted by catalym
October 26, 2023
catalym
Posted by catalym
October 16, 2023
catalym
Posted by catalym
July 20, 2023
July 20, 2023

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance

CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...

Read More
catalym
Posted by catalym
June 5, 2023
June 5, 2023

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023

CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody...

Read More
catalym
Posted by catalym
May 25, 2023
May 25, 2023

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting

CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab...

Read More
catalym
Posted by catalym
December 14, 2022
catalym
Posted by catalym
November 22, 2022
WordPress Cookie Notice by Real Cookie Banner